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Trial DesignEdoxaban for the management of elderly
Japanese patients with atrial fibrillation
ineligible for standard oral anticoagulant
therapies: Rationale and design of the
ELDERCARE-AF study
KenOkumura,MD, PhD, a Gregory Y.H. Lip b,c MasaharuAkao d KimihikoTanizawa eMasayuki Fukuzawa e Kenji Abe f
Masahiro Akishita g and Takeshi Yamashita hKumamoto, Kyoto, Tokyo, Japan; Birmingham, UK; andAalborg, DenmarkEdoxaban—a non–vitamin K antagonist oral anticoagulant (NOAC)— 60-mg and 30-mg once-daily dose regimens are
noninferior versus well-managed warfarin for the prevention of stroke or systemic embolic events (SEE) with less major bleeding
in patients with nonvalvular atrial fibrillation (NVAF). There are no published data from phase 3 clinical trials specifically
evaluating the use of NOACs in elderly NVAF patients, especially those considered ineligible for available oral
anticoagulants. The Edoxaban Low-Dose for EldeR CARE AF patients (ELDERCARE-AF) study is a phase 3, randomized,
double-blind, placebo-controlled, parallel-group, multicenter study that will compare the safety and efficacy of once-daily
edoxaban 15 mg versus placebo in Japanese patients with NVAF ≥80 years of age who are considered ineligible for standard
oral anticoagulant therapy. A total of 800 patients (400 in each treatment group) are planned for randomization (1:1) to either
edoxaban or placebo using a stratified randomization method with CHADS2 index score (2 points, ≥3 points) as a factor. The
primary efficacy end point is the time to first onset of stroke or SEE. The net clinical outcome is the composite of stroke, SEE,
major bleeding, and all-cause mortality. The primary safety end point is the incidence of major bleeding. The treatment period
will continue until 65 patients with the primary efficacy events (ie, stroke or SEE) have been observed (2- to 2.5-year expected
mean treatment period). The results of ELDERCARE-AF may provide clarity as to the efficacy and safety of edoxaban for the
prevention of stroke or SEE in this high-risk population. (Am Heart J 2017;194:99-106.)Atrial fibrillation (AF) is an independent risk factor for
stroke and systemic embolic events (SEE), and
AF-associated stroke is more likely to be fatal or disabling
compared with non-AF stroke.1,2 As the prevalence of AF
is strongly related to age worldwide, including in Japan,
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SEE.1,3-7 In one community-based study of 41,436
Japanese adults, the incidence of AF was reported to be
3.5% in men and 2.5% in women ≥80 years of age
compared with 0.5% in men and 0.2% in women aged 40
to 59 years.7
Oral anticoagulants are first-line treatment for nonvalv-
ular AF patients to reduce the risk of stroke, including in
the elderly.8,9 However, many physicians are reluctant to
prescribe oral anticoagulants to elderly patients because
of perceived contraindications such as history of bleed-
ing, prior falls, increased polypharmacy, cognitive
impairment, and frailty.10-12 In general, oral anticoagu-
lants are underused for the prevention of stroke in elderly
AF patients. 12-21 In the Fushimi AF Registry—a
community-based survey of AF patients in Japan—only
41.3% of the extremely elderly (≥85 years of age)
received oral anticoagulants alone or in combination
with antiplatelet therapy despite a significantly higher
incidence of stroke or SEE in the extremely elderly
patients versus patients ≤84 years of age.17,22 Many
extremely elderly patients are often left untreated with no
antithrombotic therapy.15-17
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December 2017Edoxaban is a direct, oral factor Xa inhibitor with linear
and predictable pharmacokinetics23 indicated for the
reduction of stroke or SEE in patients with nonvalvular
AF and for the treatment of venous thromboembolism.24 In
the Effective aNticoaGulation with factor Xa next GEner-
ation in Atrial Fibrillation–Thrombolysis In Myocardial
Infarction study 48 (ENGAGE AF-TIMI 48), edoxaban 60-
and 30-mg once-daily dose regimens were noninferior to
well-managed warfarin for the prevention of stroke or SEE
with superior safety (major bleeding).25 In this trial, the
60-mg edoxaban dose regimenwas associatedwith a lower
rate of stroke or SEE versus the 30-mg edoxaban dose
regimen.25 In a subgroup analysis of this trial, once-daily
edoxaban demonstrated consistent efficacy and safety
when comparedwithwell-managedwarfarin, regardless of
age.26 However, in ENGAGE AF-TIMI 48, only 17% of the
patients were ≥80 years of age, and the study was not
specifically designed to assess the efficacy and safety of
edoxaban in elderly patients overall or in extremely elderly
patients, who are considered ineligible for standard oral
anticoagulant therapy.26 Directly evaluating the efficacy
and safety of edoxaban in the elderly patients considered
ineligible for standard oral anticoagulant therapy will
require a sufficiently powered randomized controlled trial.
The Edoxaban Low-Dose for EldeR CARE AF patients
(ELDERCARE-AF) study is a phase 3, randomized,
double-blind, placebo-controlled, parallel-group, multicenter
study that will compare the safety and efficacy of once-daily
edoxaban 15 mg versus placebo in Japanese patients with
nonvalvular AF ≥80 years of age who are considered
ineligible for standard oral anticoagulant therapy
(ClinicalTrials.gov: NCT02801669). In this article, we sum-
marize the rationale and design of the ELDERCARE-AF study.
Objectives and study design
The primary objective of this study is to evaluate the
efficacy and safety of once-daily edoxaban 15 mg in
patients with nonvalvular AF who are ineligible for oral
anticoagulants at the approved dosage. In addition, this
study will evaluate the superiority of the 15-mg dose of
edoxaban compared with placebo for the composite
primary end point of stroke and SEE. The study will
include up to 30 days of screening and eligibility
assessment prior to randomization, an event-driven
double-blind treatment (edoxaban 15 mg or placebo)
lasting an expected mean period of 2 to 2.5 years, an
examination within 60 days after the completion of the
study, and a final follow-up examination within 30 to 37
days after the examination at the completion of the study
(Figure 1). Enrollment commenced in August 2016.
An accurate assessment of the incidence of clinical
events (eg, stroke and SEE) will require the observation of
a sufficient number of events. Therefore, this study will
not have a specified treatment duration and instead will
be event driven. Completion of the study will bedetermined when the planned number of patients that
have experienced the primary efficacy end point event
(stroke and SEE) has been observed.
Ethics and informed consent
This study was funded by Daiichi Sankyo Co Ltd (Tokyo,
Japan). Assistance in medical writing and editorial support
for this manuscript was provided by AlphaBioCom, LLC
(King of Prussia, PA), and funded by Daiichi Sankyo, Inc
(Basking Ridge, NJ). All authors materially participated in
the design and/or drafting and editing of the paper and
approved its final content. This study will be conducted in
accordance with the Good Clinical Practice standards for
drugs and the ethical principles specified in theDeclaration
of Helsinki. In addition, the storage of clinical specimens
for subsequent genomic or genetic analysis will be
conducted in accordance with the Ethical Guidelines for
Human Genome/Gene Analysis Research and the Ethical
Guidelines for Clinical Research.
The protocol has been reviewed and approved by an
institutional reviewboardprior to the start of the study.During
the course of the study, the institutional review board will
review the study at least onceper year to determinewhether it
should continue. An independent safety data monitoring
committee will monitor safety data as necessary and will
considermatters such aswhether it is possible to continue the
study and whether it is necessary to change the protocol.
Strict subject confidentiality will be maintained through
the use of subject identification codes. Informed consent
will be obtained from all participants prior to enrollment.
As the prevalence of dementia in this elderly population
may be higher than in the general population, if the
investigators consider it not feasible to obtain written
informed consent from the patient because of dementia,
they will obtain written informed consent from the
patient's legal representative.Patient population and eligibility
Male and female patients ≥80 years of age with
nonvalvular AF will be eligible to enroll if they have a
history of AF documented by any electrical tracing within
1 year of informed consent and a score of 2 or higher on
the CHADS2 risk assessment. In addition, to be included,
patients must be considered ineligible by their responsible
physician for available oral anticoagulants (ie, warfarin,
dabigatran, rivaroxaban, apixaban, or edoxaban) at
approved doses for≥1 of the following reasons: creatinine
clearance (CLCr) calculated by Cockcroft-Gault formula of
15 to 30mL/min (a common reason for nonanticoagulation
among Japanese patients due to risk of bleeding27,28); a history
of bleeding from critical organs (eg, intracranial, intraocular,
or gastrointestinal bleeding); body weight ≤45 kg; contin-
uous use of nonsteroidal anti-inflammatory medications that
are associated with bleeding while on oral anticoagulants;
Figure 1
Planned study design for the ELDERCARE-AF study. aAs the prevalence of dementia in this elderly population may be higher than in the general
population, if the investigators consider it not feasible to obtain written informed consent from the patient because of dementia, they will obtain written
informed consent from the patient's legal representative. bThis study is event driven, and study completion will be declared when the planned number of
patientswith the primary efficacy endpoint (ie, stroke or systemic embolic events) hasbeen collected; 2 to2.5 years is the expectedmean treatment period.
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than prophylaxis of cardioembolic stroke.
Renal impairment, low body weight, a history of
clinically significant bleeding, and concomitant administra-
tion of antiplatelet drugs or nonsteroidal anti-inflammatory
medications associated with bleeding while on oral
anticoagulants may increase the risk of major bleeding
during anticoagulant therapy.28-31 In the Fushimi AF
Registry, baseline body weight of AF patients was lower
in those untreated versus treated with warfarin.31 Like-
wise, in patients ≥85 years old, those not receiving
anticoagulant therapy had lower body weight versus
those on anticoagulant therapy.22 These data from
Japanese real-world studies suggest that elderly patients,
especially those with lower body weight, are under-
prescribed oral anticoagulants, including warfarin. On the
other hand, unpublished data from ENGAGE AF-TIMI 48
show that major bleeding rates in patients receiving
well-managed warfarin were higher in patients ≤45 kg
versus N45 kg (5.74%/y vs 4.82%/y). This was also observed
in patients ≥80 years of age, where major bleeding rates
were 9.20%/y versus 6.72%/y in patients≤45 kg versus N45
kg, respectively. Therefore, physicians in Japan may
consider elderly patients meeting these criteria, including
low body weight, as being ineligible for oral anticoagulants
because of these potential bleeding risks.
Table I shows the list of exclusion criteria; the
exclusion criteria were intended to be consistent with
the Japanese treatment guidelines.28 The Japanese
guidelines define nonvalvular AF as AF in patients without
prosthetic valve replacement using mechanical valves or
bioprosthetic valves, or AF in those patients without
rheumatic mitral disease.28
This study includes elderly patients with nonvalvular AF
who are considered ineligible for available oral anticoag-ulants by their responsible physician because of concerns
about bleeding or who are receiving warfarin at an
anticoagulant strength not recommended in the Japanese
guidelines (ie, international normalized ratio [INR] b1.6).28
Therefore, patients who were receiving warfarin with an
INR≥1.6 in 2 of the 3 most recent examinations, including
the eligibility assessment examination, were excluded
(patients with INR ≥1.6 at the eligibility assessment
examination were also excluded) to strictly and accurately
ensure that included patients had an INR b1.6. Othermajor
exclusion criteria include transient AF secondary to other
reversible disorders; treatment with dabigatran, rivarox-
aban, apixaban, or edoxaban within 8 weeks prior to
randomization; active bleeding on the day of informed
consent, unresolved peptic ulcer on the day of informed
consent, hemoglobinb9g/dLor platelet countb10×104 /μL
at eligibility assessment, or hereditary hemorrhagic disease;
cerebral infarction or transient ischemic attack within 30
days prior to randomization; uncontrolled hypertension;
CLCr b15mL/min; currently on ormay start hemodialysis by
the final follow-up; treatment with dual antiplatelet therapy
at the time of informed consent; hepatic function disorder
accompanied by coagulation disorder; history of myocardial
infarctionwithin 30 days prior to randomization; and serious
heart disease. During the eligibility assessment examination,
brain diagnostic imaging will be performed to confirm that
there is no active bleeding.Intervention and randomization
Patients will be randomized 1:1 to receive either
edoxaban 15 mg once daily or placebo using a stratified
randomization method with the CHADS2 index score (2
points, ≥ 3 points) as a factor. An independent
biostatistician will prepare a randomization schedule.
Table I. Exclusion criteria
Transient AF secondary to other reversible disorders
Treatment with dabigatran, rivaroxaban, apixaban, or edoxaban
≤8 wk prior to randomization
INR controlled at ≥1.6 in 2 of 3 most recent examinations in patients
randomized to warfarin, including eligibility assessment; patients
with INR ≥1.6 at eligibility assessment are excluded
Patients with particularly high bleeding risk meeting any of the following:
–Active bleeding on day of informed consent
–Unresolved peptic ulcer on day of informed consent
–Hereditary hemorrhagic disease
Cerebral infarction or TIA within 30 d prior to randomization
Rheumatic valve disease or history of cardiac valve surgery
Infective endocarditis or atrial myxoma
Left ventricular or atrial thrombus
Hereditary thrombophilia
Scheduled electrical or pharmacologic defibrillation between informed
consent and final follow-up
Uncontrolled hypertension (systolic BP persistently ≥160 mm Hg or
diastolic BP persistently N100 mm Hg)
CLCr (Cockcroft-Gault equation) b15 mL/min
Started or may start hemodialysis by final follow-up
Treatment with dual antiplatelet therapy at the time of informed consent
or expected to start treatment after informed consent
Hepatic function disorder accompanied by coagulation disorder
History of acute myocardial infarction within 30 d prior to randomization
or serious heart disease (eg, cardiac failure with New York Heart
Association classification ≥3 or unstable angina pectoris)
Diagnosed malignancy or treated with cancer therapy ≤5 y prior to
informed consent
History of receiving any other study drug within 60 d prior to informed
consent
Considered ineligible by the investigators
BP, Blood pressure; TIA, transient ischemic attack.
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because of its lower risk of bleeding in the ENGAGE
AF-TIMI 48 study compared with the 30-mg treatment
regimen, particularly in elderly patients.26,32 In ENGAGE
AF-TIMI 48, patients in the edoxaban treatment arms had
their dose halved from 60 to 30 mg in the high-dose
treatment regimen or from 30 to 15 mg in the low-dose
treatment regimen if they had CLCr 30 to 50 mL/min, low
body weight (≤60 kg), or concomitant use of specific
P-glycoprotein inhibitors.25 The incidence of major
bleeding in elderly patients (≥75 years old) receiving a
dose reduction from edoxaban 30 to 15 mg in the
low-dose treatment regimen was approximately half of
the incidence in elderly patients who were dose-reduced
from 60 to 30 mg in the high-dose treatment regimen
(1.6%/y vs 3.4%/y).26 The risk of stroke or SEE in elderly
patients with dose-reduced edoxaban 15 mg was not
significantly different to warfarin (hazard ratio [HR] 1.15,
95% CI 0.86-1.54).26
Assessments
Prior to randomization, baseline demographics and
clinical characteristics will be recorded, including vital
signs, type of AF, risk factors for thromboembolism,bleeding risk and HAS-BLED (Hypertension, Abnormal
renal/liver function, Stroke, Bleeding history or predis-
position, Labile INR, Elderly, Drugs/alcohol concomitant-
ly) score, medical history, history of oral anticoagulation
treatment, falling risk, and frailty assessment. From
initiation of treatment to study completion or discontin-
uation, study drug compliance (number of tablets
administered) will also be noted.
Efficacy events that occur between randomization and
final follow-up or discontinuation of study participation,
including stroke, SEE, myocardial infarction, transient
ischemic attack, hospitalization due to cardiovascular
disease, and all-cause mortality, will be recorded.
Similarly, all bleeding events that occur between the
initiation of treatment and final follow-up or discontinu-
ation will also be surveyed. Information regarding event
classification and details, and the situation in which the
event occurred, will be entered into the case report. All
stroke events will be assessed using the modified Rankin
Scale at approximately 1 month following stroke onset.
All bleeding events will be classified into major bleeding,
clinically relevant nonmajor (CRNM) bleeding, and minor
bleeding as defined by the International Society of
Thrombosis and Hemostasis. During study drug interrup-
tion and after study drug discontinuation, efficacy and
bleeding events will be surveyed at least every 8 weeks.
All efficacy and safety events will be adjudicated by the
independent, blinded Clinical Efficacy Event Committee
and Clinical Bleeding Event Committee, respectively.
Between the initiation of treatment and final follow-up or
discontinuation of study participation, all adverse events
will be surveyed and documented. Adverse events will be
coded using the International Conference on Harmoniza-
tion of Technical Requirements for Registration of
Pharmaceutical for Human Use Medial Dictionary for
Regulatory Activities (MedDRA). The system organ class
will be tabulated using MedDRA System Organ Class, and
adverse event terms will be tabulated using Preferred
Terms. Information that will be recorded includes the
details of the adverse event, outcome and resolution,
severity, seriousness, and causal relationship to study drug.
Body weight and blood pressure (systolic and diastolic)
will be measured at the eligibility assessment and at all
visits during the study treatment period, the examination
at study completion, and at final follow-up. Blood and
urine samples for laboratory samples will be collected
and CLCr will be calculated using Cockcroft-Gault
formula at eligibility assessment, once every 8 weeks
during study treatment, the examination at study
completion, and at final follow-up.
At week 8 of the study treatment period, the plasma
concentration of edoxaban will be measured. In addition,
citrated plasma will be collected and activated partial
thromboplastin time and prothrombin time, D-dimer, and
prothrombin fragment 1 + 2 will be assessed using
standardized laboratory methods.
Table II. Study end points
Primary efficacy end point
Composite of stroke and SEE
Primary safety end point
Major bleeding
Secondary efficacy end points
Composite of stroke, SEE, and CV mortality
Major adverse CV events
Composite of stroke, SEE, and all-cause mortality
Net clinical outcome: composite of stroke, SEE, major bleeding, and
all-cause mortality
All-cause mortality
Other efficacy end points
Hospitalization due to a CV condition (including bleeding)
Modified Rankin Scale approximately 1 m after the onset of stroke
Composite of stroke, SEE, and TIA
Number of occurrences of stroke and SEE
Venous thromboembolism (pulmonary embolism and deep vein
thrombosis)
Other safety end points







Prothrombin time and activated partial thromboplastin time
D-dimer and prothrombin fragment 1 + 2 levels
CV, Cardiovascular.
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Table II shows the list of study end points. The primary
efficacy end point is the time to first onset of the
composite end point of stroke and SEE from randomiza-
tion to the final follow-up examination or discontinua-
tion. This primary efficacy end point was chosen because
it is the standard efficacy end point that has been used in
clinical studies assessing the efficacy of anticoagulants in
patients with nonvalvular AF.33 The net clinical outcome
will be the composite of stroke, SEE, major bleeding, and
all-cause mortality.
The primary safety end point will be the incidence of
major bleeding (Table II). Other safety end points will
include the incidence of CRNM bleeding, the composite
of major and CRNM bleeding, minor bleeding, and all
bleeding. Pharmacokinetic end points will be based on
the plasma edoxaban concentration, and pharmacody-
namic end points will include activated partial thrombo-
plastin time, prothrombin time, D-dimer, and
prothrombin fragment 1 + 2.
Planned sample size
A total of 800 patients (400 in each treatment group)
are planned for randomization, and 65 primary efficacy
end points will be collected between randomization and
final follow-up.In the Fushimi AF Registry, the event rate for stroke/SEE
inpatients≥85 years of agewas 5.1 per 100patient-years.22
In ENGAGE AF-TIMI 48, the event rate in patients receiving
a dose reduction from edoxaban 30 to 15mgwas 2.36%per
year.32 From these data, it can be conservatively estimated
that edoxaban 15 mg may demonstrate a 50% risk
reduction versus the placebo group. Therefore, under the
assumption that the annual incidence of stroke or SEE is 5%
per year in patients randomized to placebo and that the HR
for the risk of stroke or SEE for edoxaban versus placebo is
0.5, 65 events will be required to evaluate superiority of
edoxaban at a 2-sided significance level of 5% and 80%
power. Approximately 400 patients will need to be
enrolled in each group, assuming that the duration of
enrollment will be 2 years and 1.5-year follow-up time. As
this is an event-driven study, the total number of patients
may change as necessary depending on the number of
target events collected. At the date of this manuscript
submission, there were 113 patients enrolled.Statistical analysis
The primary efficacy analysis will be conducted in the
intention-to-treat (ITT) population (ie, all randomized
patients) based on the randomized treatment assignment
even if patients inadvertently receive the incorrect drug
or dosage. Sensitivity analyses will be conducted in the
modified ITT (mITT) population (all randomized patients
who received ≥1 dose of study drug) and the
per-protocol set (ie, patients in the mITT who did not
have any major protocol violations). In the primary
efficacy analysis using the ITT set, the times to onset of
events will be calculated starting from the randomization
date to final follow-up examination or the examination at
discontinuation and counting all events (whether on or
off study drug). For the sensitivity analyses in the mITT
and per-protocol sets, the times to onset of events will be
calculated starting from the initiation of study treatment
to final follow-up examination or the examination at
discontinuation and counting all events (whether on or
off study drug). The safety analysis set will include all
patients who received ≥1 dose of study drug. The safety
analysis will be based on the randomized treatment unless
the patient inadvertently receives the wrong study drug
during the entire course of the study.
For the primary efficacy analysis, the time to first onset
of stroke or SEE will be analyzed using the Cox
proportional hazards model by treatment group with
CHADS2 score (≤2 or ≥3) as a covariate and tested using
a 2-sided significance level of 5%. Based on this model, HR
with 95% CI will be used to estimate the relative risk. Any
factors found to affect the primary efficacy end point in a
blinded review before the data are locked will also be
included as covariates. The cumulative incidence of
efficacy events will be estimated by treatment group
using the Kaplan-Meier method. All key secondary
Table III. Underuse of oral anticoagulants in elderly patients with nonvalvular AF
Study
Country/






Medical record review of AF patients14 Israel 1990-1998 N80 N/A 37.2%⁎ N/A N/A
Record-linkage analysis of
administrative database15
Italy 2002 ≥85 N/A 3.9% 25.1% 71.0%
REPOSI medical record database13 Italy January-December,
2008
N80 CHADS2 ≥ 2: 84.1% 29.2% 42.5% 28.3%
Cross-sectional study of AF patients aged




Mean annual stroke risk
(CHADS2): 6.9%/y
50.3% 30.1% 19.5%
Cohort study of nursing home residents
with AF12
France March 2012 Mean:
87.1
Mean CHA2DS2-VASc: 5.1 49.9% 45.5% 4.6%






J-RHYTHM Registry18 Japan January-July, 2009 ≥70 Mean CHADS2: 1.7§ 89.2% 6.9% 3.9%
Fushimi AF Registry16,17,22 Japan Enrollment: 2011-2012
Follow-up: 2013
N85 Mean CHADS2: 2.09ǁ
Mean CHA2DS2-VASc: 3.43ǁ
~40%‡ ~20%‡ ~40%‡




Median CHA2DS2-VASc: 4 29.1% 39.5% 31.4%
AP, Antiplatelet; N/A, not available; OAC, oral anticoagulant.
⁎ Percentage of patients at discharge prescribed warfarin.
†Austria, France, Germany, Italy, Spain, Switzerland, and the United Kingdom.
‡Values are for 1-year follow-up; the published manuscript that presents this data shows it in a stacked bar chart and does not provide the precise values.
§Mean CHADS2 for the entire study population (mean age 69.7).
‖Mean CHADS2 and CHA2DS2-VASc for the entire study population at baseline (mean age 74.2).
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method as the primary analysis. All other efficacy end
points will be summarized descriptively.
Bleeding events will be summarized by treatment group
and analyzed in the same fashion as the primary efficacy
end point. Adverse events, including treatment emergent
adverse events, will be tabulated by event and severity.Discussion
ELDERCARE-AF is the first phase 3, randomized,
double-blind, placebo-controlled study designed to di-
rectly assess the efficacy and safety of edoxaban for the
prevention of stroke or SEE in an elderly population. This
study will evaluate once-daily edoxaban 15 mg versus
placebo in Japanese patients ≥80 years of age with
nonvalvular AF who are considered ineligible for standard
oral anticoagulant therapy due to factors including
impaired renal function, a history of bleeding, low body
weight, and use antiplatelet drugs for a purpose other
than stroke prophylaxis. In the Japanese real-world
clinical practice, extremely elderly patients are signifi-
cantly more likely to present with many of these factors
and comorbidities versus younger patients.22 As this is an
event-driven study, the treatment period will continue
until the prespecified number of primary end point
events (ie, stroke or SEE) has been observed (expected
mean treatment period of 2-2.5 years).Current data pertaining to the efficacy and safety of
non–vitamin K antagonist oral anticoagulants (NOACs),
also referred to as direct oral anticoagulants, in elderly
patients are mainly derived from subgroup analyses of the
phase 3 clinical trials. Consistent with the overall study
results, in a subgroup analysis of ENGAGE AF-TIMI 48, the
risk of stroke or SEE in patients ≥75 years of age was
similar with edoxaban and warfarin (HR 0.83, 95% CI
0.66-1.04), and the risk of major bleeding was lower with
edoxaban (HR 0.83, 95% CI 0.70-0.99).26 Because of the
higher bleeding risk in the elderly as compared with the
younger patients, the primary net clinical outcome (ie,
stroke/SEE/major bleeding/death) of edoxaban over
warfarin was improved in older patients. Similar results
have been reported for apixaban, rivaroxaban, and
dabigatran.34-38
Elderly patients are at an increased risk of bleeding on
oral anticoagulants. In one cohort study, the incidence of
major hemorrhage in patients newly started on warfarin
was significantly higher in patients ≥80 years of age
relative to younger patients (incidence rate ratio 2.75,
95% CI 1.27-5.95).39 In addition, elderly patients have a
high number of comorbidities and contraindications,
including falls, cognitive disorder, and polypharmacy,
that may make physicians reluctant to treat elderly
patients with anticoagulants.10-12 Reflecting this, the use
of oral anticoagulants in elderly patients with nonvalvular
AF is often suboptimal worldwide, including in Japan, and
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Volume 194many elderly patients are left untreated with no
antithrombotic therapy (Table III). Furthermore, warfarin
tends to be underused in patients at high risk of stroke
and overused in those at low risk of stroke.17 However,
according to a recent registry database analysis, the
introduction of NOACs has coincided with a significant
increase in the appropriate use of anticoagulants in
elderly patients with nonvalvular AF and a CHADS2 score
≥1 (eg, in one registry: post-NOAC approval: 28.5% vs
pre-NOAC approval: 22.5%; P b .0001).40
In clinical practice, for clinicians to balance the risk of
stoke with the chance of bleeding, they need assess the
relevant data. There are currently no published clinical
data from large, double-blind, placebo-controlled, phase 3
clinical trials specifically evaluating the use of NOACs in
elderly patients with nonvalvular AF, especially in those
patients considered ineligible for available oral anticoag-
ulants. The results of ELDERCARE-AF may provide clarity
as to the efficacy and safety of edoxaban for the
prevention of stroke or SEE in this high-risk population.Conflicts of interest
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